Table 3.
The overall mean and standard deviation of dose to 98% (D98%), 95% (D95%), 1% (D1%) of clinical target volume high risk and clinical target volume low risk from the competing proton and photon plans of all five patient
| Structure | Plans | D98% (Gy RBE) protons (Gy) photons | D95% (Gy RBE) protons (Gy) photons | D1% (Gy RBE) protons (Gy) photons | |||
|---|---|---|---|---|---|---|---|
| Nominal | Worst Decrease | Nominal | Worst Decrease | Nominal | Worst Increase | ||
| CTV-HR | SFO | 58.58±8.64 | 56.05±5.59 | 62.32±9.49 | 55.43±6.51 | 77.33±1.87 | 77.87±2.18 |
| MFO | 61.73±6.57 | 56.04±6.27 | 65.44±6.66 | 56.63±6.64 | 78.50±3.08 | 79.99±3.43 | |
| HB-MFO | 63.01±7.57 | 56.86±6.63 | 66.70±7.06 | 57.60±7.15 | 78.42±3.01 | 79.38±2.67 | |
| IMRT | 60.94±9.99 | 52.06±5.32 | 64.99±8.08 | 56.06±7.42 | 79.37±3.86 | 81.07±4.09 | |
| RB-IMRT | 62.04±6.97 | 55.04±5.49 | 65.06±8.08 | 57.55±5.51 | 78.04±2.51 | 78.03±2.34 | |
| CTV-LR | SFO | 52.46±3.88 | 50.09±2.26 | 53.54±3.21 | 50.74±3.18 | 57.53±2.15 | 58.12±3.12 |
| MFO | 52.07±3.62 | 49.12±3.12 | 53.98±2.41 | 50.19±2.3 | 58.12±1.35 | 60.12±2.92 | |
| HB-MFO | 52.21±3.97 | 50.02±2.98 | 53.55±3.53 | 50.21±3.18 | 56.53±2.12 | 57.12±3.14 | |
| IMRT | 52.43±2.55 | 48.40±3.59 | 54.90±1.95 | 48.08±2.3 | 59.12±2.12 | 61.12±3.23 | |
| RB-IMRT | 52.12±3.44 | 50.14±3.13 | 53.23±2.19 | 50.12±2.49 | 56.15±2.14 | 58.12±3.32 | |
CTV-HR: Clinical target volume-high risk, CTV-LR: Clinical target volume-low risk, SFO: Single field uniform optimization, MFO: Multi field optimization, HB-MFO: Hybrid-multi field optimization, IMRT: Intensity modulated radiotherapy, RB-IMRT: Robustly optimized-intensity modulated radiotherapy, RBE: Relative biological effectiveness